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S
ince our last publication about dia-
betes and fasting during Ramadan
(1), we have received many inquires
and comments concerning important is-
sues that were not discussed in the previ-
ous document, including the voluntary
1-to2-dayfastsperweekthatmanyMus-
lims practice throughout the year, as well
as the effect of prolonged fasting (more
than 18 h a day) in regions far from the
equator during Ramadan when it occurs
in summer—a phenomenon expected to
affect millions worldwide for the next
10–15years.Since2005,therehavebeen
substantial additions to the literature, in-
cluding two studies examining the effect
of structured education and support for
safe fasting, both of which had promising
results (2,3). In addition, new medica-
tions, such as the incretin-based thera-
pies, have been introduced with less risk
for hypoglycemia.
According to a 2009 demographic
study, Islam has 1.57 billion adherents,
making up 23% of the world population
of 6.8 billion, and is growing by 3% per
year (4). Fasting during Ramadan, a holy
month of Islam, is a duty for all healthy
adult Muslims. The high global preva-
lence of type 2 diabetes—6.6% among
adults age 20–79 years (5)—coupled
with the results of the population-based
Epidemiology of Diabetes and Ramadan
1422/2001(EPIDIAR)study,whichdem-
onstrated among 12,243 people with di-
abetes from 13 Islamic countries that
43% of patients with type 1 diabetes
and 79% of patients with type 2 diabe-
tes fast during Ramadan (6), lead to the
estimate that worldwide more than 50
million people with diabetes fast during
Ramadan.
Ramadanisalunar-basedmonth,and
its duration varies between 29 and 30
days. Muslims who fast during Ramadan
mustabstainfromeating,drinking,useof
oral medications, and smoking from pre-
dawn to after sunset; however, there are
no restrictions on food or ﬂuid intake be-
tweensunsetanddawn.Mostpeoplecon-
sume two meals per day during this
month, one after sunset and the other be-
fore dawn.
Fasting is not meant to create exces-
sive hardship on the Muslim individual
according to religious tenets. Neverthe-
less,manypatientswithdiabetesinsiston
fasting during Ramadan, thereby creating
a medical challenge for themselves and
their health care providers. It is increas-
ingly important that medical profession-
als be aware of potential risks associated
withfastingduringRamadanandwithap-
proaches to mitigate those risks. These is-
sues are rapidly becoming global issues,
not only in Indonesia, Pakistan, and the
Middle East, but also in North America,
Europe, and Oceania.
Although recommendations for man-
agement of diabetes in patients who elect
to fast during Ramadan were proposed in
1995 at a conference in Casablanca (7),
our previous document was prompted by
the EPIDIAR study (6). The purpose of
this review is to evaluate new data that
has emerged since the publication of
the 2005 article and to reﬁne our
recommendations.
In this revised document, we con-
tinue to avoid use of the terms “indica-
tions” or “contraindications” for fasting
because fasting is a spiritual issue for
which patients make their own decision
after receiving appropriate advice from
religious teachings and from health care
providers. However, we emphasize that
fasting, especially among patients with
type 1 diabetes with poor glycemic con-
trol, is associated with multiple risks.
SUMMARY OF MAJOR
CHANGES AND UPDATES — The
current report:
● Addresses the voluntary 1- to 2-day
fastsperweekthatmanyMuslimsprac-
tice throughout the year
● Discusses the effect of prolonged fast-
ing(morethan18haday)inregionsfar
from the equator during Ramadan
when it occurs in summer (a phenom-
enon expected to affect millions of peo-
ple world-wide for the next 10–15
years)
● Reviewsadditionalandnovelliterature,
including studies examining the effect
ofstructurededucationandsupportfor
safe fasting
● Provides additional information in-
cluding the clinical use of new medica-
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lesserriskforhypoglycemia,suchasin-
cretin-based therapies
● Addresses safety information and the
use and limitations of existing medica-
tions such as thiazolidinediones
● Addresses the growing global scope of
the challenge of diabetes and fasting
during Ramadan—more than 50 mil-
lion people with diabetes will fast dur-
ing Ramadan in 2010
PATHOPHYSIOLOGY OF
FASTING— Insulin secretion, which
promotes the storage of glucose in liver
and muscle as glycogen, is stimulated by
feeding in healthy individuals. During
fasting, circulating glucose levels tend to
fall, leading to decreased secretion of in-
sulin. Concurrently, levels of glucagon
and catecholamines rise, stimulating the
breakdown of glycogen, and at the same
time gluconeogenesis is augmented (8).
As fasting becomes protracted for more
than several hours, glycogen stores be-
come depleted, and the low levels of cir-
culating insulin allow increased fatty acid
release from adipocytes. Oxidation of
fatty acids generates ketones that can be
used as fuel by skeletal and cardiac mus-
cle, liver, kidney, and adipose tissue, thus
sparing glucose for continued utilization
by brain and erythrocytes.
The transition from the fed state
through brief fasting and into prolonged
starvation is mediated by a series of com-
plex metabolic, hormonal, and glu-
coregulatory mechanisms. Felig (9)
convenientlydividedthetransitionfroma
fed to a fasted state into three stages:
1) thepostabsorptivephase,6–24hafter
beginning fasting
2) the gluconeogenic phase, from 2–10
days of fasting
3) the protein conservation phase, be-
yond 10 days of fasting.
Although most religious fasts seldom ex-
ceed 24 h, the variability of the duration
of every phase may lead to different phys-
iological responses to fasting. This vari-
ability may explain the feasibility of
prolonged fast even in subjects with type
1 diabetes in some studies (11). After an
overnight fast, the average rate of glucose
utilizationbyahealthyhumanis7gper
hour. By extrapolation, the 70–80 g of
glycogen present in the liver can provide
glucosetothebrainandperipheraltissues
for about 12 h (10).
In individuals without diabetes, the
processes described above are regulated
by a delicate balance between circulating
levels of insulin and counterregulatory
hormones that help maintain glucose
concentrationsinthephysiologicalrange.
In patients with diabetes, however, glu-
cose homeostasis is perturbed by the un-
derlying pathophysiology and often by
pharmacological agents designed to en-
hance or supplement insulin secretion. In
patients with type 1 diabetes, glucagon
secretion may fail to increase appropri-
ately in response to hypoglycemia. Epi-
nephrine secretion is also defective in
some patients with type 1 diabetes be-
causeofacombinationofautonomicneu-
ropathy and defects associated with
recurrent hypoglycemia (8). In patients
with severe insulin deﬁciency, a pro-
longed fast in the absence of adequate in-
sulin can lead to excessive glycogen
breakdown and increased gluconeogene-
sis and ketogenesis, leading to hypergly-
cemia and ketoacidosis. Patients with
type 2 diabetes may suffer similar pertur-
bations in response to a prolonged fast;
however, ketoacidosis is uncommon, and
the severity of hyperglycemia depends on
the extent of insulin resistance and/or
deﬁciency.
In a recent study, normal volunteers
were subjected to intermittent 20-h fasts
every2nddayfor15dayswhilemaintain-
ing body weight. Plasma free fatty acid
and -hydroxybutyrate concentrations
increased after 20 h of fasting, conﬁrming
that the subjects were fasting. Insulin-
mediated whole-body glucose rates in-
creased and insulin-induced inhibition of
lipolysis in adipose tissue was more
prominent after than before the interven-
tion. After the 20-h fasting periods,
plasma adiponectin was increased com-
pared with the basal levels before and af-
ter the intervention. This experiment was
the ﬁrst to show in humans that intermit-
tent fasting increases insulin-mediated
glucose uptake rates, compatible with
the thrifty gene concept (12). Limited
human data suggests higher HDL cho-
lesterol and lower triacylglycerol con-
centrations but no effect on blood
pressurefromfasting.Intermsofcancer
risk, there is no human evidence to date
of the effects of fasting. However, ani-
mal studies found decreases in lym-
phoma incidence, longer survival after
tumor inoculation, and lower rates of
proliferation of several cell types (13).
RISKS ASSOCIATED WITH
FASTING IN PATIENTS
WITH DIABETES— Fasting during
Ramadan has been uniformly discour-
aged by the medical profession for pa-
tients with diabetes. In keeping with this,
a large epidemiological study conducted
in13Islamiccountrieson12,243diabetic
individuals who fasted during Ramadan
showedahighrateofacutecomplications
(6). However, a few studies on this topic
using relatively small groups of patients
suggest that complication rates may not
be signiﬁcantly increased (14–18). Some
ofthemajorpotentialcomplicationsasso-
ciated with fasting in patients with diabe-
tes are outlined in Table 1.
Hypoglycemia
Decreased food intake is a well-known
risk factor for the development of hypo-
glycemia (19). It has been estimated that
hypoglycemiaaccountsfor2–4%ofmor-
talityinpatientswithtype1diabetes(20).
There are no reliable estimates concern-
ing the contribution of hypoglycemia to
mortalityintype2diabetes;however,itis
felt that hypoglycemia is an infrequent
cause of death in this group of patients.
Rates of hypoglycemia are several-fold
lower in patients with type 2 compared
with type 1 diabetes (6), and rates are
even lower in patients with type 2 diabe-
tes treated with oral agents (21).
The effect of fasting during Ramadan
on rates of hypoglycemia in patients with
diabetes is not known with certainty. The
largest dataset is the recent EPIDIAR
study (6), which showed that fasting dur-
ing Ramadan increased the risk of severe
hypoglycemia (deﬁned as hospitalization
due to hypoglycemia) some 4.7-fold in
patientswithtype1diabetes(from3to14
events   100 people
1   month
1) and
7.5-fold in patients with type 2 diabetes
(from 0.4 to 3 events   100 people
1  
month
1). The incidence of severe hypo-
glycemiawasprobablyunderestimatedin
this study because events requiring assis-
tance from a third party without the need
for hospitalization were not included. Al-
though the average A1C in these patients
at the beginning of Ramadan was not
given,itisunlikelythatthepatientsinthis
Table 1—Major risks associated with fasting
in patients with diabetes
Hypoglycemia
Hyperglycemia
Diabetic ketoacidosis
Dehydration and thrombosis
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hypoglycemia was more frequent in pa-
tients in whom the dosage of oral hypo-
glycemic agents or insulin were changed
and in those who reported a signiﬁcant
change in their lifestyle (6).
Hyperglycemia
Long-term morbidity and mortality stud-
ies in people with diabetes, such as the
DiabetesControlandComplicationsTrial
(DCCT) and the UK Prospective Diabetes
Study (UKPDS), demonstrated the link
among hyperglycemia, microvascular
complications, and possibly macrovascu-
lar complications (19,22). However,
there is no information linking repeated
yearly episodes of short-term hyperglyce-
mia (e.g., 4-week duration) and diabetes-
related complications. Control of
glycemia in patients with diabetes who
fastedduringRamadanhasbeenreported
to deteriorate, improve, or show no
change (21–25). The extensive EPIDIAR
study showed a ﬁvefold increase in the
incidence of severe hyperglycemia (re-
quiring hospitalization) during Ramadan
inpatientswithtype2diabetes(from1to
5 events   100 people
1   month
1) and
an approximate threefold increase in the
incidenceofseverehyperglycemiawithor
withoutketoacidosisinpatientswithtype
1 diabetes (from 5 to 17 events   100 peo-
ple
1   month
1) (6). Hyperglycemia
mayhavebeenduetoexcessivereduction
in dosages of medications to prevent hy-
poglycemia. Patients who reported an in-
crease in food and/or sugar intake had
signiﬁcantly higher rates of severe hyper-
glycemia (6).
Diabetic ketoacidosis
Patients with diabetes, especially those
with type 1 diabetes, who fast during Ra-
madan, are at increased risk for develop-
mentofdiabeticketoacidosis,particularly
if their diabetes is poorly controlled be-
foreRamadan(6).Inaddition,theriskfor
diabetic ketoacidosis may be further in-
creased due to excessive reduction of in-
sulin dosages based on the assumption
that food intake is reduced during the
month.
Dehydration and thrombosis
Limitation of ﬂuid intake during the fast,
especiallyifprolonged,isacauseofdehy-
dration.Thedehydrationmaybecomese-
vereasaresultofexcessiveperspirationin
hot and humid climates and among indi-
viduals who perform hard physical labor.
In addition, hyperglycemia produces an
osmotic diuresis, further contributing
to volume and electrolyte depletion.
Orthostatic hypotension may develop,
especially in patients with preexisting
autonomic neuropathy. Syncope, falls,
injuries, and bone fractures may result
from hypovolemia and the associated hy-
potension. In addition, contraction of the
intravascularspacecanfurtherexacerbate
the hypercoagulable state that is well
demonstrated in diabetes (23). Increased
blood viscosity secondary to dehydration
may enhance the risk of thrombosis and
stroke (24). A report from Saudi Arabia
suggested an increased incidence of reti-
nal vein occlusion in patients who fasted
duringRamadan(25).However,hospital-
izations due to coronary events or stroke
were not increased during Ramadan (26).
There are no data concerning the effect of
fasting on mortality in patients with or
without diabetes.
MANAGEMENT— It is worth re-
emphasizing that fasting for patients with
diabetesrepresentsanimportantpersonal
decision that should be made in light of
guidelines for religious exemptions and
after careful consideration of the associ-
ated risks in consultation with health care
providers.Mostoften,themedicalrecom-
mendation will be to not undertake fast-
ing. However, patients who insist on
fasting need to be aware of the associated
risks of the fasting experience and tech-
niques to decrease this risk. Patients may
be at higher or lower risk for fasting-
related complications depending on the
number and extent of their risk factors.
Conditions associated with “very high,”
“high,” “moderate,” and “low” risk for ad-
verse events in patients with type 1 or
type 2 diabetes who decide to fast during
Ramadan are listed in Table 2.
General considerations
Several important issues deserve special
attention.
Individualization. Perhaps the most
crucial issue is the realization that care
must be highly individualized and that
the management plan will differ for each
speciﬁc patient.
Frequent monitoring of glycemia. It is
essential that patients have the means to
monitor their blood glucose levels multi-
ple times daily. This is especially critical
in patients with type 1 diabetes and in
patients with type 2 diabetes who require
insulin.
Nutrition. During Ramadan there is a
major change in the dietary pattern com-
pared with other times of the year. Most
health problems are likely to arise from
inappropriate diet or as a consequence of
over-eating and insufﬁcient sleep. There-
fore, the diet during Ramadan for people
with diabetes should not differ signiﬁ-
cantly from a healthy and balanced diet.
The nutritional advice should be tailored
to their special needs and medical prob-
lems. It should aim at maintaining a con-
stant body mass. In most studies, 50–
60% of individuals who fast maintain
their body weight during the month,
while 20–25% either gain or lose weight
(6). The common practice of ingesting
large amounts of foods rich in carbohy-
drates and fats, especially at the sunset
Table 2— Categories of risk in patients with
type 1 or type 2 diabetes who fast during
Ramadan
Very high risk
Severe hypoglycemia within the 3 months
prior to Ramadan
A history of recurrent hypoglycemia
Hypoglycemia unawareness
Sustained poor glycemic control
Ketoacidosis within the 3 months prior to
Ramadan
Type 1 diabetes
Acute illness
Hyperosmolar hyperglycemic coma within
the previous 3 months
Performing intense physical labor
Pregnancy
Chronic dialysis
High risk
Moderate hyperglycemia (average blood
glucose 150–300 mg/dl or A1C
7.5–9.0%)
Renal insufﬁciency
Advanced macrovascular complications
Living alone and treated with insulin or
sulfonylureas
Patients with comorbid conditions that
present additional risk factors
Old age with ill health
Treatment with drugs that may affect
mentation
Moderate risk
Well-controlled diabetes treated with
short-acting insulin secretagogues
Low risk
Well-controlled diabetes treated with
lifestyle therapy, metformin, acarbose,
thiazolidinediones, and/or incretin-
based therapies in otherwise healthy
patients
Note: This classiﬁcation is based largely on expert
opinionandnotonscientiﬁcdataderivedfromclin-
ical studies.
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delay in digestion and absorption, inges-
tionoffoodscontaining“complex”carbo-
hydrates (slow digesting foods) may be
advisable at the predawn meal, which
should be eaten as late as possible before
the start of the daily fast. It is also recom-
mended that ﬂuid intake be increased
during nonfasting hours.
Exercise. Normal levels of physical ac-
tivity may be maintained. However, ex-
cessive physical activity may lead to a
higher risk of hypoglycemia and should
be avoided, particularly during the few
hours before the sunset meal. Quite com-
monly,multipleprayersareperformedaf-
terthesunsetmeal;thisgenerallyinvolves
repeated cycles of rising, kneeling, and
bowing and should be considered a part
of the daily exercise program. In some
patients with poorly controlled type 1
diabetes, exercise may lead to severe
hyperglycemia.
Breaking the fast. All patients should
understandthattheymustalwaysandim-
mediately end their fast if hypoglycemia
(blood glucose of 60 mg/dl [3.3 mmol/
l]) occurs because their blood glucose
may drop further if they delay treatment.
The fast should also be broken if blood
glucose reaches 70 mg/dl (3.9 mmol/l)
in the ﬁrst few hours after the start of the
fast, especially if insulin, sulfonylurea
drugs, or meglitinide are taken at pre-
dawn.Finally,thefastshouldbebrokenif
blood glucose exceeds 300 mg/dl (16.7
mmol/l). Patients should avoid fasting on
“sick days.”
Pre-Ramadan medical assessment
Allpatientswithdiabeteswhowishtofast
during Ramadan should prepare by un-
dergoing a medical assessment and en-
gaging in a structured education program
to undertake the fast as safely as possible.
This assessment should take place 1–2
months before Ramadan. Speciﬁc atten-
tionshouldbedevotedtopatients’overall
well-being and to the control of their gly-
cemia, blood pressure, and lipids. Appro-
priate blood studies should be ordered
and evaluated. Speciﬁc medical advice
must be provided to individual patients
concerning the potential risks they must
accept if they decide to fast. During this
assessment, necessary changes in diet or
medication regimen should be made so
that the patient initiates fasting while on a
stable and effective program. This assess-
ment should also extend to those who
do not wish to fast because they often are
exposed to the risk of hypo- and hyper-
glycemia during Ramadan as a reﬂection
of social habits encountered during the
month.
Ramadan-focused structured
diabetes education
The role of structured education for pa-
tients is well established in the manage-
ment of diabetes. This should be
extended to Ramadan-focused diabetes
education. Many Muslims with diabetes
are very passionate about fasting during
Ramadan.Thispassionisagoldenoppor-
tunity to empower people with diabetes
for better management of their diabetes,
not only during Ramadan but also
throughout the year. However, many
healthcareprofessionalsﬁndthattheyare
unable to give the appropriate medical
adviceduetolackofknowledgeaboutthe
optimum management of diabetes while
fasting. Indeed, often people with diabe-
tes feel that there is lack of harmony be-
tween the medical and the religious
advice they receive. Hence, a Ramadan-
focused diabetes educational program
should ideally include three components:
1) An awareness campaign aimed at peo-
ple with diabetes, health care profes-
sionals, the religious and community
leaders as well as the general public
2) Ramadan-focused structured educa-
tion for health care professionals
3) Ramadan-focused structured educa-
tion for people with diabetes.
RaisingthegeneralawarenessofRamadan
and diabetes should strengthen the har-
mony between medical and religious ad-
vice. This is of particular importance in
non-Muslim countries where poor com-
munication and understanding between
these communities is commonplace.
Greater understanding regarding the reli-
gious context and perspective regarding
Ramadan and the act of fasting, as well as
the potential risks and the medical op-
tions to achieve a safer outcome for those
who wish to fast, is critical for all parties.
Health care professionals should be
trained to deliver a structured patient ed-
ucation program that includes a better
understanding of fasting and diabetes, in-
dividual risk quantiﬁcation, and options
to achieve safer fasting. This includes the
importance of glucose monitoring during
fasting and nonfasting hours, when to
stop the fast, meal planning to avoid hy-
poglycemia and dehydration during pro-
longed fasting hours, and the appropriate
mealchoicestoavoidpostprandialhyper-
glycemia. The educational program
should include advice on the timing and
intensity of physical activity during fast-
ing. Certainly, it is important that use of
diabetes-related medications and their
potential risk during fasting are also
discussed.
A well-trained health care profes-
sional should be able to deliver all these
components to people with diabetes ei-
ther individually or in a group session at
diabetes centers, primary health care cen-
ters, local mosques, and/or community
centers. The ability to deliver this educa-
tional program in a simple, structured
methodandinthepatients’ownlanguage
is a distinct advantage, especially in mul-
tilingualcommunities.Certainly,manyof
the components of the program will help
empower people with diabetes to take
better care of themselves throughout the
year.
An example of such an educational
program, which involves increasing
awareness and training for health care
professionals and the local community
about diabetes and Ramadan through a
structured education program, was con-
ducted in 2007 in the U.K. for a group of
111 people with type 2 diabetes (2).
Though the group excluded people
treated with insulin, secretagogues were
used in over 90% of the people. Individ-
ualized medication dose adjustments
were suggested to all patients. At the end
of Ramadan, when compared with a con-
trol group comprising those who did not
participate in the Ramadan-focused dia-
betes education, those who received such
education exhibited a nearly 50% reduc-
tion in hypoglycemic event rates despite
fasting, whereas those in the control
group had experienced a fourfold in-
crease in the rate of hypoglycemic events
from baseline during fasting. It is impor-
tant to note that this occurred while gly-
cemic control was maintained at the same
level for 12 months (2). Furthermore, the
group that received structured education
lost a small amount of weight compared
to weight gain in the control group (27).
Management of patients with type 1
diabetes
Fasting at Ramadan carries a very high
risk for people with type 1 diabetes. This
risk is particularly exacerbated in poorly
controlledpatientsandthosewithlimited
access to medical care, hypoglycemic un-
awareness, unstable glycemic control, or
recurrent hospitalizations. In addition,
the risk is also very high in patients who
Management of diabetes during Ramadan
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blood glucose levels several times daily. It
is currently recommended that treatment
regimens aimed at intensive glycemia
management be used in patients with di-
abetes. The DCCT and its follow up, the
Epidemiology for Diabetes Interven-
tions and Complications (EDIC) study,
demonstrated that intensive glycemia
management is protective against mi-
crovascular and perhaps macrovascular
complications and that the beneﬁts are
long lasting (19,28). Glycemic control at
near-normal levels requires use of multi-
pledailyinsulininjections(threeormore)
or use of continuous subcutaneous insu-
lininfusionthroughpumptherapy.Close
monitoring and frequent insulin dose ad-
justments in this setting are essential to
achieve optimal glycemic control and
avoid hypo- or hyperglycemia in patients
with type 1 diabetes.
Some patients with type 1 diabetes
prefer to fast at Ramadan, and most of
them change their insulin regimens im-
mediately before, during, and a few days
after this month. However, very few stud-
ies have documented the safety and/or ef-
ﬁcacyofdifferentinsulinregimensintype
1 diabetic patients who fast during the
month of Ramadan. The current under-
standingisthatthebasal-bolusregimenis
the preferred protocol of management. It
isthoughttobesafer,withfewerepisodes
ofhyper-andhypoglycemia.Afrequently
used option is once- or twice-daily injec-
tions of intermediate or long-acting insu-
lin along with premeal rapid-acting
insulin. It is unlikely that other regimens,
including one or two injections of inter-
mediate-, long-acting, or premixed insu-
lin, would provide adequate insulin
therapy.Arecentsmallstudywithinsulin
glargine suggests the relative safety and
efﬁcacy of this agent in 15 relatively well-
controlled patients with type 1 diabetes
who fasted for 18 h and experienced a
minimal decline in mean plasma glucose
from 125 to 93 mg/dl with only two epi-
sodes of mild hypoglycemia (29). An-
other study in patients with type 1
diabetes using insulin glulisine, lispro, or
aspart instead of regular insulin in com-
bination with intermediate-acting insulin
injected twice a day led to improvement
in postprandial glycemia and was associ-
ated with fewer hypoglycemic events
(30). Clinical studies with other types of
insulin in multiple daily injection regi-
mens during fasting are limited.
Continuous subcutaneous insulin
infusion (pump) management is an ap-
pealingalternativestrategy,butatasub-
stantially greater expense. Compared
with those who did not fast during Ra-
madan, patients with type 1 diabetes on
insulin pump therapy who fasted showed
a slight improvement in A1C (3).
Management of patients with type 2
diabetes
Diet-controlled patients. In patients
with type 2 diabetes who are well con-
trolled with lifestyle therapy alone, the
risk associated with fasting is quite low.
However, there is still a potential risk for
occurrence of postprandial hyperglyce-
mia after the predawn and sunset meals if
patients overindulge in eating. Distribut-
ing calories over two to three smaller
meals during the nonfasting interval may
help prevent excessive postprandial hy-
perglycemia. Physical activity may be
modiﬁed in its intensity and timing, e.g.,
2 h after the sunset meal.
Patients treated with oral agents. The
choice of oral agents should be individu-
alized. In general, agents that act by in-
creasing insulin sensitivity are associated
with a signiﬁcantly lower risk of hypogly-
cemia than compounds that act by in-
creasing insulin secretion.
Metformin. Patients treated with met-
formin alone may safely fast because the
possibilityofseverehypoglycemiaismin-
imal. However, perhaps the timing of the
doses should be modiﬁed to provide two-
thirds of the total daily dose with the sun-
set meal and the other third before the
predawn meal.
Glitazones. The thiazolidinedione or gli-
tazone agents (pioglitazone and rosiglita-
zone) are not independently associated
with hypoglycemia, though they can am-
plifythehypoglycemiceffectsofsulfonyl-
ureas, glinides, and insulin. However,
they are associated with weight gain and
anecdotally can be associated with in-
creased appetite. The longstanding con-
cerns regarding cardiovascular safety,
caused by the increased frequency of
heart failure, continue despite greater un-
derstanding that the mechanism of this
adverse effect seems to be related to renal
tubular sodium and water reabsorption
and not to an intrinsic affect on cardiac
contractility. More recently, apprehen-
sion has emerged regarding reports of in-
creased frequency of macular edema and
of bone fractures, particularly in post-
menopausal women. The recent contro-
versy regarding the cardiovascular safety
of rosiglitazone seems to have been
largely mitigated by the Rosiglitazone
Evaluated for Cardiovascular Outcomes
and Regulation of Glycaemia in Diabetes
(RECORD)study,whichfailedtodemon-
strate either harm or beneﬁt. Neverthe-
less, most perceive a relative advantage of
pioglitazone compared with rosiglitazone
vis-a `-vis lipid effects. A practical issue of
signiﬁcant importance with respect to the
utility of glitazones in periods of fasting
such as Ramadan is that these agents re-
quire 2–4 weeks to exert substantial an-
tihyperglycemic effects. Therefore, these
agents cannot be quickly substituted for
agentsassociatedwithhypoglycemiadur-
ing periods of fasting (31).
Sulfonylureas. It has been suggested that
this group of drugs is unsuitable for use
duringfastingbecauseoftheinherentrisk
ofhypoglycemia.However,severeorfatal
hypoglycemia is a relatively rare compli-
cation of sulfonylurea use. Nevertheless,
their use should be individualized with
caution. Use of chlorpropamide is rela-
tively contraindicated during Ramadan
because of the possibility of prolonged
and unpredictable hypoglycemia. Simi-
larly, it has been suggested that glyburide
orglibenclamidemaybeassociatedwitha
higher risk of hypoglycemia than other
second-generation sulfonylureas, speciﬁ-
cally gliclazide, glimepiride, and glipizide
(32,33). Finally, it should be noted that
the sulfonylureas glyburide (gliben-
clamide) and gliclazide MR have played a
central role in the long-term outcome
studiesUKPDSandADVANCE(Actionin
Diabetes and Vascular Disease: Preterax
and Diamicron MR Controlled Evalua-
tion),bothofwhichdemonstratedmicro-
vascular beneﬁts and at least trends
toward improvements in cardiovascular
disease without evidence of excess mor-
tality (34). Additional studies on the use
of sulfonylureas in patients who fast dur-
ing Ramadan are needed before strong
recommendations on their utility can be
made. Nevertheless, because of their
worldwide use and relatively low cost,
these agents may be used in Ramadan,
though with caution.
Short-acting insulin secretagogues.
Members of this group (repaglinide and
nateglinide) are useful because of their
short duration of action. They could be
taken twice daily before the sunset and
predawn meals. One study in patients
with type 2 diabetes who fasted showed
that use of repaglinide was associated
with less hypoglycemia compared with
glibenclamide (35). Nateglinide has the
shortest duration of action and therefore
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Incretin-based therapy. Therapies that
affect the incretin system include gluca-
gon-like peptide-1 receptor agonists
(GLP-1ras) exenatide and liraglutide and
dipeptidylpeptidase-4 inhibitors (DPP-
4is) alogliptin, saxagliptin, sitagliptin,
and vildagliptin. These classes of agents
arenotindependentlyassociatedwithhy-
poglycemia, though they can increase the
hypoglycemic effects of sulfonylureas,
glinides, and insulin. Exenatide in partic-
ular can be dosed before meals to mini-
mize appetite and promote weight loss.
With its short half-life of 2 h, it is not
associatedwithasubstantialeffectonfast-
ing glucose. Liraglutide is dosed once a
day, independent of meals, and is more
effective in controlling fasting glycemia.
Both require titration to effective doses
over a period of 2–4 weeks and are asso-
ciated with mild to moderate nausea in
almost half of those exposed on at least
one occasion, particularly as therapy is
initiated. DPP-4is are among the best tol-
erateddrugsforthetreatmentofdiabetes.
They are moderately less effective in A1C
lowering than GLP-1ras and, importantly
vis-a `-vis treatment during Ramadan, do
not require titration. Many have touted
their potential role as a substitute for sul-
fonylureas.However,therearenospeciﬁc
studies of these agents during periods of
fasting with respect to either tolerability
or efﬁcacy (36).
-Glucosidase inhibitors. Acarbose,
miglitol, and voglibose slow the absorp-
tion of carbohydrates when taken with
the ﬁrst bite of a meal. Because they are
not associated with an independent risk
of hypoglycemia, particularly in the fast-
ing state, they may be particularly useful
during Ramadan. However, they are only
modestly effective and exert little or no
effectonfastingglucose,andthereforeare
usually used in combination with other
agents to control fasting glucose. -Glu-
cosidase inhibitors are associated with
frequent mild to moderate gastro-
intestinal effects, particularly ﬂatulence.
Using modest doses and slowly initiating
therapy are reported to minimize the fre-
quency of these adverse effects (37).
Patients treated with insulin. Prob-
lems facing patients with type 2 diabetes
who administer insulin are similar to
thosewithtype1diabetes,exceptthatthe
incidence of hypoglycemia is less. Again,
the aim is to maintain necessary levels of
basal insulin to prevent fasting hypergly-
cemia. An effective strategy would be ju-
dicious use of intermediate- or long-
acting insulin preparations plus a short-
acting insulin administered before meals.
Although hypoglycemia tends to be less
frequent, it is still a risk, especially in pa-
tients who have required insulin therapy
for a number of years or in whom insulin
deﬁciency predominates in the patho-
physiology. Very elderly patients with
type 2 diabetes may be at especially high
risk.
Using one injection of a long-acting
or intermediate-acting insulin can pro-
vide adequate coverage in some patients
as long as the dosage is appropriately in-
dividualized; however, most patients will
require rapid- or short-acting insulin ad-
ministered in combination with the basal
insulin at meals, particularly at the
evening meal, which typically contains a
larger caloric load. There is some evi-
dence suggesting that use of a rapid-
acting insulin analog instead of regular
human insulin before meals in patients
with type 2 diabetes who fast during Ra-
madan is associated with less hypoglyce-
mia and smaller postprandial glucose
excursions (38,39). In a recent study, the
use of premixed lispro with neutral pro-
tamine lispro in a 50:50 ratio for the
evening meal and regular human insulin
with NPH in a 30:70 ratio at the early
morning meal during Ramadan com-
pared with regular human insulin at
30:70 twice daily was associated with
moderate improvement in glycemic con-
trol and hypoglycemia (40).
Insulin pumps. An insulin pump pro-
vides continuous insulin delivery over
24 h with basal infusion rates pro-
grammed and individualized for each pa-
tient. Patients self-administer boluses of
insulinwithmealsorattimesofhypergly-
cemia, often with mathematical support
from the pump. The reliance on exclu-
sively rapid-acting or short-acting insulin
allows for ﬂexibility over an extremely
wide range of insulin doses with great
precision. However, frequent glucose
monitoring is required because failure of
thepumportheinfusionsitecanresultin
severe deterioration in control over a few
hours. Theoretically, the combined risks
of hypoglycemia from prolonged daytime
fasting and hyperglycemia from excessive
nighttime eating can be better managed
by an insulin pump–based regimen than
by multiple insulin dose–injection ther-
apy. Hypoglycemia can be aborted, re-
duced, prevented, and even more readily
treated in pump-treated patients by
timely downward adjustments or even
stopping insulin delivery from the pump.
Such an advantage is not available to
those treated with a conventional insulin
injection in which insulin continues to be
released from the site of injection
throughoutitspredetermineddurationof
action. Any excess insulin action can
only be counteracted by intake of
carbohydrates.
Fasting at Ramadan may be success-
fully accomplished in people with type 1
diabetesiftheyarefullyeducatedandfac-
ile with the use of the insulin pump and
are otherwise metabolically stable and
free from any acute illnesses. Prior to Ra-
madan, they should receive adequate
training and education, particularly with
respect to self-management and insulin
dose adjustment. They should adjust
their infusion rates carefully according to
results of frequent home blood glucose
monitoring. Most will need to reduce
their basal infusion rate while increasing
the bolus doses to cover the predawn and
sunset meals.
Diabetic medication adjustment
during Ramadan
Illustrative examples and recommenda-
tions for adjusting therapy during Ra-
madaninpatientswithtype2diabetesare
shown in Table 3.
Pregnancy and fasting during
Ramadan
Pregnancy is a state of increased insulin
resistance and insulin secretion and of re-
duced hepatic insulin extraction. Fasting
glucose concentrations are lower and
postprandial glucose and insulin levels
are substantially higher in healthy preg-
nant women than in healthy women who
are not pregnant. Elevated blood glucose
and A1C levels in pregnancy are associ-
atedwithincreasedriskformajorcongen-
ital malformations. Fasting during
pregnancy would be expected to carry a
highriskofmorbidityandmortalitytothe
fetus and mother, although controversy
exists (41). While pregnant Muslim
women are exempt from fasting during
Ramadan, some with known diabetes
(type 1, type 2, or gestational) insist on
fasting. These women constitute a high-
risk group, and their management re-
quires intensive care (42).
In general, women with pregesta-
tional or gestational diabetes are at very
highriskandmaybestronglyadvisednot
to fast during Ramadan. However, if they
insist on fasting, special attention should
be given to their care. Pre-Ramadan eval-
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sential.Thisincludespreconceptioncare
with emphasis on achieving near-normal
blood glucose and A1C values, counsel-
ing about maternal and fetal complica-
tions associated with poor glycemic
control, and education focused on self-
management skills. Ideally, patients
should be managed in high-risk clinics
staffed by an obstetrician, diabetologists,
a nutritionist, and diabetes nurse educa-
tors. The management of pregnant pa-
tients during Ramadan is based on an
appropriate diet and intensive insulin
therapy. The issues discussed above con-
cerning the management of type 1 and
type 2 diabetes also apply to this group,
with the exception that more frequent
monitoring and insulin dose adjustment
is necessary.
Management of hypertension and
dyslipidemia
Dehydration, volume depletion, and a
tendency toward hypotension may occur
withfastingduringRamadan,especiallyif
the fast is prolonged and is associated
with excessive perspiration. Hence, the
dosage and/or the type of antihyperten-
sive medications may need to be adjusted
to prevent hypotension. Diuretics may
not be appropriate during Ramadan for
some patients. It is a common practice
that the intake of foods rich in carbohy-
drates and saturated fats is increased dur-
ing Ramadan. Appropriate counseling
shouldbegiventoavoidthispractice,and
agentsthatwerepreviouslyprescribedfor
the management of elevated cholesterol
and triglycerides should be continued.
CONCLUSIONS— Fasting during
Ramadan for patients with diabetes car-
ries a risk of an assortment of complica-
tions. In general, patients with type 1
diabetes are at very high risk of life-
threatening complications. Patients with
type 1 diabetes who have a history of re-
current hypoglycemia or hypoglycemia
unawareness or who are poorly con-
trolledareatveryhighriskfordeveloping
severe hypoglycemia. On the other hand,
an excessive reduction in the insulin dos-
age in these patients (to prevent hypogly-
cemia) may place them at risk for
hyperglycemia and diabetic ketoacidosis.
Hypo- and hyperglycemia may also occur
in patients with type 2 diabetes, but is
generally less frequent and has less severe
consequencesthaninpatientswithtype1
diabetes. A patient’s decision to fast
should be made after ample discussion
with a health care provider concerning
the risks involved. Patients who insist on
fasting should undergo pre-Ramadan as-
sessment and receive appropriate edu-
cation and instructions related to
physical activity, meal planning, glu-
cosemonitoring,anddosageandtiming
of medications.
Newer pharmacological agents have
lesser hypoglycemic potential and may
have speciﬁc advantages during Ra-
madan. Similarly, insulin pump therapy
may provide greater safety in the Ra-
madan setting. There are a few studies of
these newer techniques in the Ramadan
setting with encouraging results, but in
general this challenging therapeutic situ-
ation has not been adequately addressed
in clinical trials.
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